CCCC
C4 Therapeutics, Inc.
$3.58
-0.28%
$396.9M
No data for this timeframe.
Vol
Market Cap$396.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders8 funds
Inst. Value$38.9M
Inst. Activity6 buys / 0 sells
SEC Reports6
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001662579·Prev Close $3.59
Recent Activity
Jun 8, 2026
short_volume
Short Volume: CCCC — 55.4% short (0.5M / 1.0M)
Short: 547,344 | Exempt: 437 | TRF Vol: 987,213 | Short Ratio: 55.4% | Off-exchange volume (dark poo
Jun 1, 2026
Insider
Anderson Kenneth Carl sold 1,070 shares
Director @ $2.11 ($2.3K)
Jun 1, 2026
Insider
Anderson Kenneth Carl sold 1,070 shares
Director @ $0.00 ($0.00)
May 15, 2026
SEC
C4 Therapeutics disclosed the departure of Chief Accounting Officer Mark Mossler, effective May 15, 2026, with no disagr
8-K — Impact 2/10
May 12, 2026
SEC
C4 Therapeutics reported Q1 2026 revenue of $6.2M (down 14% YoY from $7.2M) and a net loss per share of -$0.20 (improved
8-K — Impact 4/10
May 12, 2026
SEC
C4 Therapeutics reported Q1 2026 results with an EPS beat ($-0.18 vs $-0.26 consensus) and revenue beat ($6.2M vs $4.4M
PRESS-RELEASE — Impact 5/10
Apr 1, 2026
Insider
Anderson Kenneth Carl sold 4,259 shares
Director @ $2.70 ($11.5K)
Inst.
MORGAN STANLEY — ADD
8,981,662 shares ($17.2M)
Price Targets
$12.29
+243.2% upside
Strong Buy
Current $3.58
Low $6.00
Median $10.00
High $30.00
7 analysts
$6.00
$30.00
Analyst Ratings
5Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 1, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
| Feb 27, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Feb 23, 2026 | Brookline Capital | MAINTAIN | Buy → Buy |
| Dec 17, 2025 | Barclays | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.24 ▲ +18.6% | $-0.28 — $-0.20 | 35% YoY | 3 |
| Next Q | $-0.27 ▲ +9.6% | $-0.29 — $-0.25 | 10% YoY | 3 |
| Current FY | $-0.99 ▲ +11.2% | $-1.06 — $-0.90 | 13% YoY | 4 |
| Next FY | $-1.16 ▲ +8.1% | $-1.45 — $-0.93 | -17% YoY | 4 |
Latest Reports
NEUTRAL
8-K
2/10
C4 Therapeutics disclosed the departure of Chief Accounting Officer Mark Mossler, effective May 15, 2026, with no disagr
May 15, 2026
NEUTRAL
8-K
4/10
C4 Therapeutics reported Q1 2026 revenue of $6.2M (down 14% YoY from $7.2M) and a net loss per share of -$0.20 (improved
May 12, 2026
BULLISH
Press
7/10
C4 Therapeutics announced a collaboration with Roche to develop degrader-antibody conjugates (DACs) for two oncology tar
Apr 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $17.2M | ADD |
| VANGUARD GROUP INC | $8.4M | ADD |
| BANK OF AMERICA CORP | $4.6M | — |
| RENAISSANCE TECHNOLOGIES LLC | $3.1M | ADD |
| TWO SIGMA INVESTMENTS, LP | $2.9M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Anderson Kenneth | M | $2.3K |
| Jun 1, 2026 | Anderson Kenneth | M | $0.00 |
| Apr 1, 2026 | Anderson Kenneth | A | $11.5K |
| Apr 1, 2026 | GROGAN DONNA | A | $14.5K |
8 institutional holders with $38.9M total value (20,374,344 shares) as of 2025-Q4. Top holders: MORGAN, VANGUARD, BANK. Net buying activity: 6 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 8,981,662 | $17.2M | 44.1% | ADD +80.6% |
| 2 | VANGUARD GROUP INC | 4,379,815 | $8.4M | 21.5% | ADD +37.2% |
| 3 | BANK OF AMERICA CORP /DE/ | 2,387,586 | $4.6M | 11.7% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 1,602,580 | $3.1M | 7.9% | ADD +71.0% |
| 5 | TWO SIGMA INVESTMENTS, LP | 1,509,603 | $2.9M | 7.4% | ADD +80.9% |
| 6 | WELLS FARGO & COMPANY/MN | 809,260 | $1.5M | 4.0% | DOUBLED +4236.9% |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 449,432 | $858.4K | 2.2% | ADD +28.2% |
| 8 | FMR LLC | 254,406 | $485.9K | 1.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 4,972,032 | 8,981,662 | +80.6% | $17.2M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 3,191,557 | 4,379,815 | +37.2% | $8.4M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 936,950 | 1,602,580 | +71.0% | $3.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 834,726 | 1,509,603 | +80.9% | $2.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 18,660 | 809,260 | +4236.9% | $1.5M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 350,606 | 449,432 | +28.2% | $858.4K | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 572,026 | 61,650 | -89.2% | $136.9K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,529 | 18,660 | +1120.4% | $41.4K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 214,500 | 1,093,188 | +409.6% | $1.6M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 514,603 | 683,599 | +32.8% | $977.5K | 2025-Q2 |
| UBS Group AG | TRIM | 872,770 | 572,026 | -34.5% | $818.0K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 474,843 | 331,897 | -30.1% | $474.6K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 523,619 | 1,529 | -99.7% | $2.2K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 36,306 | 523,619 | +1342.2% | $837.8K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 214,500 | — | $343.2K | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 157,416 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | ADD | 2,326,134 | 3,839,469 | +65.1% | $13.8M | 2024-Q4 |
| UBS Group AG | DOUBLED | 334,081 | 757,852 | +126.8% | $2.7M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 26,917 | 36,306 | +34.9% | $130.7K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 1,137,938 | 2,326,134 | +104.4% | $13.3M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 482,929 | — | $2.8M | 2024-Q3 |
2 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Anderson Kenneth Carl | Director | M | 1,070 | $2.11 | $2.3K |
| Jun 1, 2026 | Anderson Kenneth Carl | Director | M | 1,070 | $0.00 | $0.00 |
| Apr 1, 2026 | Anderson Kenneth Carl | Director | A | 4,259 | $2.70 | $11.5K |
| Apr 1, 2026 | GROGAN DONNA ROY | Director | A | 5,370 | $2.70 | $14.5K |
6 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 5.2/10.
NEUTRAL
8-K
2/10
C4 Therapeutics disclosed the departure of Chief Accounting Officer Mark Mossler, effective May 15,
May 15, 2026
NEUTRAL
8-K
4/10
C4 Therapeutics reported Q1 2026 revenue of $6.2M (down 14% YoY from $7.2M) and a net loss per share
May 12, 2026
MIXED
PRESS-RELEASE
5/10
C4 Therapeutics reported Q1 2026 results with an EPS beat ($-0.18 vs $-0.26 consensus) and revenue b
May 12, 2026
BULLISH
8-K
7/10
C4 Therapeutics entered a research collaboration and license agreement with Roche to develop degrade
Apr 9, 2026
BULLISH
INST-CLUSTER
6/10
Three major institutional investors — Morgan Stanley, Wells Fargo, and UBS — increased their positio
Feb 28, 2026
BULLISH
8-K
7/10
C4 Therapeutics reported financial results for Q4 and full year 2025, highlighted by a 112% YoY incr
Feb 26, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 5 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$12.29 mean target
+243.2% upside
Strong Buy (1.13)
$6.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $3.58 |
| Target Low | $6.00 |
| Target Mean | $12.29 |
| Target Median | $10.00 |
| Target High | $30.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.13) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.24 | $-0.28 | $-0.20 | 35.1% | +18.6% | 1↑ 0↓ | $0.0B | -35.0% | 3 |
| Next Q 2026-09-30 |
$-0.27 | $-0.29 | $-0.25 | 9.7% | +9.6% | — | $0.0B | -58.5% | 3 |
| Current FY 2026-12-31 |
$-0.99 | $-1.06 | $-0.90 | 13.2% | +11.2% | 1↑ 1↓ | $0.0B | -46.1% | 4 |
| Next FY 2027-12-31 |
$-1.16 | $-1.45 | $-0.93 | -17.2% | +8.1% | 1↑ 1↓ | $0.0B | 3.9% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.240 | |
| 7d ago | $-0.295 | +0.055 |
| 30d ago | $-0.295 | +0.055 |
| 60d ago | $-0.330 | +0.090 |
| 90d ago | $-0.320 | +0.080 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 1, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Feb 27, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Feb 23, 2026 | Brookline Capital | MAINTAIN | Buy | Buy |
| Dec 17, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
short_volume
Short Volume: CCCC — 55.4% short (0.5M / 1.0M)
Short: 547,344 | Exempt: 437 | TRF Vol: 987,213 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 20, 2026
other
C4 Therapeutics to Participate in Upcoming Conferences
<p>WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicat
May 18, 2026
activist
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicat
May 12, 2026
earnings
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
<p align="left">WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical co
May 5, 2026
earnings_calendar
CCCC Q1 2026 Earnings Scheduled — 2026-05-05
Apr 14, 2026
short_volume
Short Volume: CCCC — 55.9% short (1.3M / 2.3M)
Short: 1,298,206 | Exempt: 12,711 | TRF Vol: 2,322,095 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: CCCC — 60.4% short (2.0M / 3.3M)
Short: 1,985,225 | Exempt: 45,619 | TRF Vol: 3,286,945 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
Apr 9, 2026
contract
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
<p align="center"><em>Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target</em></p>
Mar 25, 2026
fda
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy <pre>Novel Combination Regimen Positions Cemsidomide for Use in Ea
Mar 9, 2026
other
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedic
Feb 25, 2026
earnings_calendar
CCCC Q4 2025 Earnings After Market Close — 2026-02-25